Time to Listen

The new era of 2.0 technologies has welcomed the science
of pharmacovigilance (PV) with increasing interest from
regulatory agencies, pharmaceutical companies, healthcare
providers and patients, who may be seen as the leaders of
this evolution – as consumers of health-related products, the
collective voice of patients is having a significant impact. This
is contemporary to an observed shift from evidence-based
medicine towards real world evidence and observational
studies. In these, a study’s design is more fitted to patient life
than in controlled clinical trials, where eligible participants
must adapt to study settings.

Social media platforms, like Facebook, Twitter, and
Instagram, along with health-related websites and forums,
such as PatientsLikeMe or pharma-sponsored websites,
offer large forums of expression where any health-related
idea or concern may be shared, including adverse events
attributed to medications.

As Senior Safety Scientist at UBC, Caroline Legendre is responsible for supporting operational PV functions, including client interface, deliverables related to product safety and safety signal detection and assessment. She has 10 years of experience in the global pharmaceutical industry, with expertise in vaccines, pre- and post-marketing PV and pharmacoepidemiology.

Alexis Pinçon is Safety Physician at UBC and responsible for providing medical support to operational PV functions. He completed his medical training at the University of Lyon, France, and received his Master of Public Health from Université Besançon (Franche-Comté) in 2007. He has 10 years’ experience in PV within the pharma industry, primarily focused on vaccines in both clinical development and post-marketing.

November 16, 2017, Oxford, England and San Francisco, US. – Oxford
Genetics, a leader in innovative synthetic biology-based technologies
for biologics discovery, development and delivery, announced today a new
licensing agreement with Twist Bioscience Corporation, a company
enabling customers to succeed through its offering of rapid,
high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience
with its SnapFast™ technology platform to provide
a broad range of application-specific expression vectors which Twist
Bioscience will use to clone synthesized DNA for its diverse customer
base. More info >>

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.More info >>

Biotech Showcase™
is an investor and partnering conference devoted to providing private and
small- and mid-cap biotechnology companies an opportunity to present to and
meet with investors and biopharmaceutical executives during the course of one
of the largest annual healthcare conferences that attracts investors and
biopharmaceutical executives from around the world.More info >>